

Supplementary Table 3, related to Figure 3, clinical parameters of 12 HIV-1 infected individuals under suppressive antiretroviral therapy.

Participants #	age	sex	HIV-1 seropositivity (months)	Phase at treatment initiation ⁽¹⁾	Treatment (months)	Aviremia (months)	CD4 T cell count (cells/mm ³)	Plasma HIV-RNA (copies/ml)
27	46	F	224	C	101	72	788	<20
45	59	M	313	C	215	89	799	<20
62	43	M	61	P	61	60	890	<20
489	25	M	55	P	55	43	530	<20
566	41	M	48	C	47	16	260	33
658	48	M	35	P	34	29	682	<20
706	37	M	29	C	29	25	1249	<20
724	50	M	23	P	23	17	1138	<20
768	40	M	35	C	21	15	1362	<20
769	41	M	16	P	15	10	934	<20
771	37	M	21	P	21	14	522	<20
776	43	M	35	P	34	26	666	<20
Mean	43		75		55	34	818	
Median	42		35		34	26	794	

(1) C, Chronic infection. P, Primary infection.

In some participants (2), treatment was initiated during (C) chronic or (P) primary infection.

Supplementary Table 4 CD32a^{hi} subset proportions and infection frequencies compared to total CD4 T cells and CD32a-depleted CD4 T cells.

Participants ID	CD32a ^{hi} % among CD4 ⁺ T cells*	HIV-DNA copies/ CD32a ^{hi} cells	HIV-DNA enrichment	
			CD32a ^{hi} / total CD4 T cells	CD32a ^{hi} / CD32a ^{neg} cells
27	0.03 (1,000)	0.445	74.6	135.5
45	0.002 (2,000)	0.053	10.5	35.3
62	0.01 (580)	2.524	53.1	386.4
489	0.026 (996)	0.603	2,098.9	1,343.1
566	0.042 (1,000)	0.242	38.9	34.9
658	0.014 (1,978)	0.181	326.7	709.3
706	0.007 (1,000)	0.902	785.7	1,068.7
724	0.007 (2,264)	3.024	1,098.4	4,197.6
768	0.019 (1,188)	1.675	2,682.5	3,178.1
769	0.022 (2,502)	0.061	22.5	30.8
771	0.009 (9,723)	0.511	301.6	535.6
776	0.004 (800)	0.94	102.7	643.5
Mean	0.016	0.93	633	1,024.9
Median	0.012	0.557	202.15	589.5

* Absolute cell number is indicated in bracket